Alemtuzumab: Key for Minimization of Maintenance Immunosuppression in Reconstructive Transplantation?

S. Schneeberger; L. Landin; C. Kaufmann; V. S. Gorantla; G. Brandacher; P. Cavadas; W. P.A. Lee; W. C. Breidenbach; R. Margreiter

doi:10.1016/j.transproceed.2009.01.018

Alemtuzumab: Key for Minimization of Maintenance Immunosuppression in Reconstructive Transplantation?

S. Schneeberger, L. Landin, C. Kaufmann, V. S. Gorantla, G. Brandacher, P. Cavadas, W. P.A. Lee, W. C. Breidenbach, R. Margreiter

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

Minimization of immunosuppression has become the key effort in solid organ transplantation. Alemtuzumab, the humanized CD-52 monoclonal antibody, is an effective depleting agent increasingly used in transplantation trials. In this article, we summarize the current experience with alemtuzumab use in hand transplantation and discuss its role in current and future approaches toward minimization of maintenance immunosuppression in reconstructive transplantation.

Original language	English (US)
Pages (from-to)	499-502
Number of pages	4
Journal	Transplantation Proceedings
Volume	41
Issue number	2
DOIs	https://doi.org/10.1016/j.transproceed.2009.01.018
State	Published - Mar 1 2009
Externally published	Yes

ASJC Scopus subject areas

Surgery
Transplantation

Access to Document

10.1016/j.transproceed.2009.01.018

Fingerprint Dive into the research topics of 'Alemtuzumab: Key for Minimization of Maintenance Immunosuppression in Reconstructive Transplantation?'. Together they form a unique fingerprint.

Cite this

Alemtuzumab : Key for Minimization of Maintenance Immunosuppression in Reconstructive Transplantation? / Schneeberger, S.; Landin, L.; Kaufmann, C.; Gorantla, V. S.; Brandacher, G.; Cavadas, P.; Lee, W. P.A.; Breidenbach, W. C.; Margreiter, R.

In: Transplantation Proceedings, Vol. 41, No. 2, 01.03.2009, p. 499-502.

Research output: Contribution to journal › Article › peer-review

@article{d6beb3cf449c400f8214a4c92d327fb6,

title = "Alemtuzumab: Key for Minimization of Maintenance Immunosuppression in Reconstructive Transplantation?",

abstract = "Minimization of immunosuppression has become the key effort in solid organ transplantation. Alemtuzumab, the humanized CD-52 monoclonal antibody, is an effective depleting agent increasingly used in transplantation trials. In this article, we summarize the current experience with alemtuzumab use in hand transplantation and discuss its role in current and future approaches toward minimization of maintenance immunosuppression in reconstructive transplantation.",

author = "S. Schneeberger and L. Landin and C. Kaufmann and Gorantla, {V. S.} and G. Brandacher and P. Cavadas and Lee, {W. P.A.} and Breidenbach, {W. C.} and R. Margreiter",

year = "2009",

month = mar,

day = "1",

doi = "10.1016/j.transproceed.2009.01.018",

language = "English (US)",

volume = "41",

pages = "499--502",

journal = "Transplantation Proceedings",

issn = "0041-1345",

publisher = "Elsevier USA",

number = "2",

}

TY - JOUR

T1 - Alemtuzumab

T2 - Key for Minimization of Maintenance Immunosuppression in Reconstructive Transplantation?

AU - Schneeberger, S.

AU - Landin, L.

AU - Kaufmann, C.

AU - Gorantla, V. S.

AU - Brandacher, G.

AU - Cavadas, P.

AU - Lee, W. P.A.

AU - Breidenbach, W. C.

AU - Margreiter, R.

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Minimization of immunosuppression has become the key effort in solid organ transplantation. Alemtuzumab, the humanized CD-52 monoclonal antibody, is an effective depleting agent increasingly used in transplantation trials. In this article, we summarize the current experience with alemtuzumab use in hand transplantation and discuss its role in current and future approaches toward minimization of maintenance immunosuppression in reconstructive transplantation.

AB - Minimization of immunosuppression has become the key effort in solid organ transplantation. Alemtuzumab, the humanized CD-52 monoclonal antibody, is an effective depleting agent increasingly used in transplantation trials. In this article, we summarize the current experience with alemtuzumab use in hand transplantation and discuss its role in current and future approaches toward minimization of maintenance immunosuppression in reconstructive transplantation.

UR - http://www.scopus.com/inward/record.url?scp=62849099728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62849099728&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2009.01.018

DO - 10.1016/j.transproceed.2009.01.018

M3 - Article

C2 - 19328912

AN - SCOPUS:62849099728

VL - 41

SP - 499

EP - 502

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 2

ER -